What Is 150 Milligrams About?
The premise of 150 Milligrams in 260 words, with nothing given away. The full story follows below.
In the crisp, rain‑kissed streets of Brest, a university hospital pulses with the relentless rhythm of modern medicine. Within its sterile corridors, Dr. Irène Frachon moves with the confidence of a seasoned pulmonologist, her day‑to‑day defined by the precision of diagnoses and the quiet urgency of life‑saving procedures. The film drapes this clinical world in a subdued, almost documentary texture, letting the hum of monitors and the hushed conversations of staff set a tone that feels both intimate and foreboding.
It is amid this routine that Frachon begins to notice a troubling pattern: patients treated for unrelated ailments share an unexpected heart condition, all of whom have been prescribed the same state‑approved medication. The discovery flickers like a warning light, prompting her to step beyond bedside care and into the realm of epidemiological sleuthing. The hospital’s corridors give way to archives, data rooms, and hushed meetings, where the line between scientific curiosity and moral imperative blurs, hinting at forces that would prefer the anomaly stay unnoticed.
Compelled by a blend of professional duty and personal conviction, Frachon assembles a small but steadfast circle, including Dr. Antoine Le Bihan, whose methodical approach grounds her fervor. Together they navigate a labyrinth of bureaucratic protocols and corporate caution, each step echoing the solitary nature of her quest. The atmosphere is one of quiet determination, where the stakes feel enormous despite the restrained visual style, and where the promise of truth hangs in the air like an unspoken oath—setting the stage for a confrontation between unwavering inquiry and the shadowed weight of powerful interests.
What Happens in 150 Milligrams?
The complete story of 150 Milligrams, from the first scene to the last, in 758 words (about 3 minutes). Spoilers throughout. Names in the text link to 7 cast member pages.
Spoilers ahead
Sidse Babett Knudsen stars as Dr. Irène Frachon, a pulmonologist at a university hospital in Brest, in northern France. The film opens in a high-stakes medical setting, where surgeons perform open-heart procedures, immediately signaling the life-and-death rhythm of modern medicine. Frachon begins to notice a troubling pattern: Corinne Zacharria, Isabelle de Hertogh—a patient she treats—shows severely damaged heart valves, a condition appearing across several patients who have taken Mediator, a drug developed by Servier for diabetes and weight loss. The scenes in the hospital ward set a meticulous, patient-centered tone, and Frachon’s sharp clinical eye drives the investigation from the very first diagnosis.
Driven by what she sees in the clinic, Frachon pursues a broader answer: is Mediator really behind these serious heart problems? She pursues epidemiological evidence, gathering data, and assembling a network of colleagues who share her concern. Among them, Dr. Antoine Le Bihan, Benoît Magimel, emerges as a crucial ally, bringing rigorous research methods and a steady voice to the growing case. Together, they begin to connect isolated medical anomalies into a coherent pattern, translating bedside worry into bedside science. Their collaboration deepens as the data accumulate, reinforcing Frachon’s hypothesis in a way that cannot be dismissed.
When the team presents their findings to AFSSAPS, the regulatory body responsible for health products in France, they encounter stiff scrutiny from Servier’s representatives. The film lays bare the friction between patient safety and corporate interests, a tension that complicates the path to a decisive warning. Despite clear signals from the data, the regulators are reluctant to remove Mediator from the market, and the initial push to pull the drug proves difficult. The procedural drama—filled with expert testimony, subtle political maneuvering, and the sting of corporate pushback—filters through Frachon’s circle and colors every interaction with regulators, clinicians, and patients alike. The sense of persistence and moral urgency remains front and center, even as obstacles mount.
Unbowed, Frachon presses forward beyond the confines of the hospital. She publicly records the journey through a self-published book detailing the research and the stories behind the cases, hoping to empower patients and alert the broader health community. Servier fights back against the publication, elevating the stakes and broadening the public conversation around drug safety. The effort garners support from a diverse network: journalist Anne Jouan, Lara Neumann of Le Figaro, who helps bring crucial attention to the case; AFSSAPS member Dr Catherine Haynes, Myriam Azencot; and a CNAM informant who provides essential data that helps triangulate the findings. This coalition—comprising clinicians, journalists, regulators, and insiders—gives Frachon a human-centered, multi-perspective vantage on the fight for accountability.
As the investigative drumbeat continues, the film foregrounds the human costs of delay: the months and years of effort behind each datapoint, the strain on Frachon’s family, and the mounting pressure to prove a link that could alter regulatory and corporate futures. Against this backdrop, the mortar of the narrative remains the stark statistic that emerges from the investigation: Mediator is linked to around 500 deaths, most of them among women. The scope of the tragedy sharpens Frachon’s resolve and reframes the discourse on drug safety, shifting the story from a personal crusade to a public health imperative.
In the end, the movie does more than recount a battle between a clinician and a pharmaceutical giant. It dramatizes a systemic struggle—between patient welfare and market forces, between precaution and speed, between individual courage and institutional inertia. The outcome is not wrapped in a neat verdict, but the film leaves a lasting impression about the importance of independent inquiry, rigorous science, and transparent regulation. It honors the tireless work of those who seek the truth despite formidable resistance, and it invites viewers to consider how many lives depend on the integrity of medical oversight and the responsible stewardship of new therapies.
The story is anchored by a constellation of performances that ground the emotional impact in real-world gravity. Benoît Magimel brings a steady, methodical counterpoint to Frachon’s relentless drive, while Philippe Uchan embodies the calculated pressure of corporate messaging. The cast surrounding Frachon—Myriam Azencot as Catherine Haynes, Lara Neumann as Anne Jouan, and Gilles Treton as Dr Yannick Jobic—helps to illuminate the wide network of professionals and stakeholders who shape the course of events. The film’s visual language—clinical detail, documentary pacing, and restrained emotional arousal—keeps the focus on evidence, consequence, and the human story behind every statistic. In this way, it not only reports a medical saga but also invites viewers to reflect on how society answers the question of risk, responsibility, and reform in the pharmaceutical era.
150 Milligrams Timeline: Every Key Event in Order
14 key events in the order they happen, from “Opening surgery observation” to “A turning point toward ongoing scrutiny”. 14 events name a place, across 4 locations.
- 1
Opening surgery observation
In the university hospital in Brest, doctors perform open-heart surgery. Dr. Irene Frachon observes that the heart valves of patient Corinne Zacharria appear severely damaged. She notes this valve damage in other patients who had taken Mediator, suggesting a possible link between the drug and the heart condition.
When:opening scene Where:Brest, Northern France
- 2
Pattern across patients and hypothesis
Irene realizes the pattern extends beyond a single case and there are multiple Mediator users with similar heart damage. She determines that an epidemiological study is needed to prove the link.
When:early investigation Where:France (across multiple hospitals)
- 3
Formation of the research team
A research team forms, bringing together several colleagues who contribute to the investigation. Dr. Antoine Le Bihan's work is highlighted as especially significant in building the study.
When:shortly after Where:Brest, Northern France
- 4
Findings support the hypothesis
Their research findings strongly support Irene's hypothesis that Mediator is linked to the heart pathology. The team compiles epidemiological evidence across cases to demonstrate the connection.
When:during data collection Where:Brest, Northern France
- 5
Presenting to the regulator
They present their findings to AFSSAPS, the French health regulatory agency, in hopes of regulatory action. Servier's representatives scrutinize the presentation and push back against the conclusions.
When:after findings presented Where:Paris, France
- 6
Regulatory setback
Despite the intense scrutiny, Mediator is not removed from the market, leaving Irene disappointed but undeterred. She remains committed to pursuing the evidence and advocating for patient safety.
When:after regulatory scrutiny Where:Paris, France
- 7
Persistence in the face of inertia
Irene presses on with her campaign, drawing support from her family and colleagues. She refuses to back down in the face of regulatory inertia.
When:following regulatory inertia Where:Brest, Northern France
- 8
Self-published book
Irene self-publishes a book detailing their research and the team’s findings. Servier responds with legal pressure in an attempt to halt publication.
When:after book publication Where:Brest, Northern France
- 9
Media attention and support
A Le Figaro reporter, Anne Jouan, supports the investigation and helps bring attention to it. Her coverage amplifies public scrutiny of Mediator's risks.
When:after media involvement Where:France
- 10
Regulatory and clinical support
An AFSSAPS member, Catherine Haynes, offers support to the effort, bolstering the regulatory side of the inquiry. Her involvement signals some regulators' alignment with the clinicians' concerns.
When:after media involvement Where:France
Show the other 4 events of 150 Milligrams Hide the last 4 events
- 11
Health-insurance data support
A CNAM informant from the national health insurance fund backs the investigation. The informant provides data and context from the health system to strengthen the epidemiological case.
When:after CNAM backing Where:France
- 12
Deaths linked to Mediator revealed
The investigation reveals around 500 deaths connected to Mediator. Most of the victims are women.
When:late in the investigation Where:France
- 13
The gravity of the issue
The scale of the deaths underscores the gravity of the issue and the stakes of regulatory debate. Irene remains determined to pursue justice and safer drug practices.
When:late in the investigation Where:France
- 14
A turning point toward ongoing scrutiny
The revelations set the stage for ongoing scrutiny of drug safety and the handling of such cases in France. Irene's work leaves a lasting impact on how patient safety cases are approached.
When:conclusion Where:France
Who Are the Main Characters in 150 Milligrams?
5 characters, among them Dr Irène Frachon - Sidse Babett Knudsen, Dr Antoine Le Bihan - Benoît Magimel and Corinne Zacharria - Isabelle de Hertogh: who each one is and the part they play in the story. Every profile links to the actor’s page.
-
Dr Irène Frachon - Sidse Babett Knudsen
Played by Sidse Babett Knudsen
A determined pulmonologist and whistleblower who connects Mediator to damaging heart valve conditions. She is persistent, principled, and willing to confront powerful entities to protect patients.
- 💡 Investigator
- 🧭 Ethics
- 🩺 Medical Research
-
Dr Antoine Le Bihan - Benoît Magimel
Played by Benoît Magimel
A research scientist whose collaboration helps translate clinical observations into epidemiological data. He plays a key role in building the evidence base while navigating scientific challenges.
- 🔬 Research
- 🧪 Collaboration
- 🧭 Peer Support
- CZ
Corinne Zacharria - Isabelle de Hertogh
Played by Isabelle de Hertogh
A patient whose condition contributes to the early pattern prompting investigation. Her case personifies the human impact behind pharmacovigilance debates.
- ❤️ Patient
- 🧬 Case Study
- AJ
Anne Jouan - Lara Neumann
Played by Lara Neumann
A Le Figaro journalist who helps bring the findings to the public eye, balancing scrutiny with sensitivity to the scandal’s consequences.
- 📰 Journalism
- 🗞 Public Pressure
- CH
Catherine Haynes - Myriam Azencot
Played by Myriam Azencot
An epidemiologist collaborating with the team to construct the epidemiological study needed to prove the drug safety concerns.
- 📊 Epidemiology
- 🧠 Analysis
Where and When Is 150 Milligrams Set?
150 Milligrams is set in Brest and Northern France (2000s). Here is why the time and place matter to the story.
When
2000s
The events take place during the late 2000s as clinicians pursue epidemiological evidence linking a controversial drug to heart damage. Regulators and industry press are part of the backdrop as researchers push for accountability. The timeline follows the emergence of public health concerns and the fight to publish findings.
Where
Brest, Northern France
The story unfolds at the university hospital in Brest, a major city in Brittany, northern France. It centers on the medical facilities where Dr. Frachon conducts her investigations. The hospital setting emphasizes patient care and the environment where clinical observations become evidence.
- 🏥 Hospital
- 🇫🇷 France
- 🗺 Brest
What Are the Themes of 150 Milligrams?
4 ideas the story keeps returning to, among them Whistleblowing, Regulation vs Industry and Public Health.
-
01
Whistleblowing
A dedicated physician challenges a powerful pharmaceutical narrative, risking professional and personal fallout to expose safety issues. The theme centers on integrity, courage, and the costs of speaking truth to power.
-
02
Regulation vs Industry
The film portrays the friction between regulatory bodies and pharmaceutical interests. It highlights how policy, evidence, and corporate influence shape public health decisions.
-
03
Public Health
Epidemiological work and patient safety take prominence as the team links the drug to harm and seeks to prevent further deaths. The focus is on protecting communities through data-driven action.
-
04
Truth through Research
Credible science and rigorous study underpin the struggle for transparency. The narrative underscores the responsibility of researchers to publish findings that inform and safeguard patients.
What Kind of Film Is 150 Milligrams?
Tense in tone, with steady pacing and a moderate story, going by the plot summary.
- Tone
- Tense
- Pacing
- Steady
- Story
- Moderate
- Intensity
- High
- Ending
- Bittersweet
A steady-paced and emotionally heavy drama that generates tense frustration through its depiction of a doctor's solitary, determined fight against a powerful pharmaceutical company and bureaucratic inertia.
- tense
- urgent
- frustrating
- solitary
- determined
- gripping
- whistleblower
- corporate malfeasance
- medical drama
- fighting the system
Content notes: death, corporate negligence, medical harm.
Quiz
How well do you remember 150 Milligrams? Test yourself on the story.
